Feb 13–16, 2028 | Fairmont Monte Carlo, Monte Carlo, Monaco
Scientific Organizers:
Christopher D. Buckley, Ellen M. Gravallese, and Luke Devey
-
Scientific Organizers: Christopher D. Buckley, Ellen M. Gravallese, and Luke Devey
Christopher D. Buckley, PhD
Kennedy Institute of Rheumatology
Ellen M. Gravallese, MD
Brigham and Women's Hospital
Luke Devey, MD, PhD
Quell Therapeutics
***Meeting program subject to change.
Available Formats: = Livestream = In Person = On DemandMerchandise Options
Registration Options
Sunday, February 13, 2028
Monday, February 14, 2028
From Autologous CAR-T to Programmable Immune Reset: The Next Era of Cell Therapy in Autoimmunity
Inborn Errors of Immunity as Windows into Autoimmunity and Autoinflammation
From Genetic Risk to Pathogenic Macrophage Programs: ETS2 and Therapeutic Targets in IBD
Interferon and Innate Signalling at Mucosal Barriers: From Host Defence to Inflammation
Microbiota–Innate Immune Circuits in Barrier Inflammation
Cell-Intrinsic Immunity and Intracellular Stress: New Entry Points into Chronic Inflammation
Tuesday, February 15, 2028
Tissue Damage, Repair, and Therapeutic Response in Inflammatory Arthritis
Human Tissue Immunity in IBD: Linking Mucosal Cell States to Treatment Response
From Inflammasome Biology to Biomarkers, Patient Stratification, and Targeted Therapy
The Cellular Basis of persistent Inflammation and its Location: From Tissue Niches to Therapeutic Targets
Immune Agonism and Regulatory Pathways as Therapeutic Strategies in Autoimmunity
Resetting the Tissue: Targeting Fibroblasts to Provide New Medicines for Fibrotic and Autoimmune Disease
Wednesday, February 16, 2028
Deep B-Cell Depletion and Immune Reset with CAR-T in Lupus and Systemic Sclerosis
Off-the-Shelf Immune Reset with CD19- and BCMA-Directed T-Cell Engagers in Autoimmune Disease
Engineered Regulatory T Cells: Can Tolerance Replace Depletion?
Antigen-Specific Cellular Therapy for Autoantibody-Mediated Disease: From CAAR-T to Next-Generation Immune Engineering
In Vivo CAR-T for Autoimmunity: Turning Cell Therapy into a Scalable, Off-the-Shelf Medicine
Allogeneic Gamma-Delta CAR-T for Lupus and Systemic Sclerosis: Toward an Off-the-Shelf Immune Reset
Engineering Myeloid Cells to Reprogram Fibrotic and Inflamed Tissues
Thursday, February 17, 2028
Subscribe for Updates